Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Colorcon
Express Scripts
McKesson
Baxter

Last Updated: January 31, 2023

Details for Patent: 7,855,211


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,855,211 protect, and when does it expire?

Patent 7,855,211 protects VERZENIO and is included in one NDA.

This patent has fifty patent family members in forty-four countries.

Summary for Patent: 7,855,211
Title:Protein kinase inhibitors
Abstract: The present invention provides a compound of formula (I): ##STR00001## or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
Inventor(s): Coates; David A (Indianapolis, IN), Gelbert; Lawrence Mark (Indianapolis, IN), Knobeloch; John M. (Indianapolis, IN), De Dios Magana; Alfonso (Carmel, IN), De Prado Gonzalez; Ana (Madrid, ES), Filadelfa Del Prado Catalina; Miriam (Madrid, ES), Garcia Paredes; Maria Cristina (Madrid, ES), Martin De La Nava; Eva Maria (Madrid, ES), Martin Ortega Finger; Maria Dolores (Madrid, ES), Martinez Perez; Jose Antonio (Madrid, ES), Mateo Herranz; Ana Isabel (Madrid, ES), Perez Martinez; Carlos (Madrid, ES), Sanchez Martinez; Concepcion (Madrid, ES)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:12/637,789
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 7,855,211

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER See Plans and Pricing
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY See Plans and Pricing
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING See Plans and Pricing
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20% See Plans and Pricing
Eli Lilly And Co VERZENIO abemaciclib TABLET;ORAL 208716-001 Sep 28, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDROCRINE THERAPY See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,855,211

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08380343Dec 22, 2008

International Family Members for US Patent 7,855,211

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 074575 See Plans and Pricing
Australia 2009330365 See Plans and Pricing
Brazil PI0924183 See Plans and Pricing
Canada 2747055 See Plans and Pricing
Chile 2011001527 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
McKesson
Merck
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.